Skip to content
Open access

Characteristics and outcomes of NATALEE- and monarchE-eligible early breast cancer in Finland: a regional real-world cohort study

Oct 2026 · The Oncologist · Vol 31 · 0 citations · 36 references
Medicine

TL;DR

Real-world outcomes among NATALEE and monarchE-eligible patients are consistent with results from phase III trial comparator arms, and both NATALEE and monarchE eligibility were associated with distant metastasis, and mortality.

Abstract

Abstract Background Adjuvant cyclin-dependent kinases 4 and 6 (CDK4/6) inhibitors have improved outcomes in hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2–) early breast cancer (eBC) in the NATALEE and monarchE trials. However, real‑world evidence on the proportion of candidates for adjuvant CDK4/6 inhibitors and their outcomes within these trial-defined populations remains limited. Materials and Methods We conducted a retrospective, population‑based cohort study including all patients diagnosed with HR+/HER2– eBC in the Hospital District of Helsinki and Uusimaa, Finland, between January 2014 and June 2023. Patients were classified according to NATALEE and/or monarchE eligibility criteria. Outcomes assessed were invasive disease‑free survival (iDFS), distant disease‑free survival (DDFS), and overall survival (OS). Results Among 8911 patients with HR+/HER2- eBC and a median follow-up of 5.2 years, 40.4% met the NATALEE eligibility criteria and 15.0% met the monarchE criteria. Eligible patients were younger and had higher‑grade tumors and greater proliferation rate than non-eligible patients. Five‑year outcomes were consistently worse in eligible than ineligible patients (NATALEE: iDFS 82.5% vs 89.6%, DDFS 88.3% vs 94.5%, OS 90.9% vs 95.6%; monarchE: iDFS 76.8% vs 88.4%, DDFS 82.3% vs 93.8%, OS 86.8% vs 94.9%). Metastatic progression occurred 3‑ to 6‑fold more often in eligible patients. In multivariable models, both NATALEE and monarchE eligibility were associated with distant metastasis, and mortality. Conclusion Real-world outcomes among NATALEE and monarchE-eligible patients are consistent with results from phase III trial comparator arms. Trial‑defined eligibility criteria reliably identify patients with substantially poorer prognosis, supporting risk‑adapted adjuvant strategies and the integration of CDK4/6 inhibitors into clinical practice.

Read PDF

Similar papers

Open access Oct 2026

Treatment Outcomes of Patients with Early-Stage Breast Cancer Meeting NATALEE Eligibility Criteria. A Real-World Cohort Study

The findings provide real-world historical outcome data for patients who would now be considered candidates for adjuvant ribociclib and may serve as a benchmark for evaluating outcomes following adoption of adjuvant ribociclib.

H. Abdel-Razeq, M. Horani, F. Tamimi et al. · 0 citations
Open access Oct 2026

Overall survival with adjuvant ribociclib plus nonsteroidal aromatase inhibitor in patients with high-risk HR+/HER2- early breast cancer: Six-year follow-up of the NATALEE trial.

Positive OS results with a clinically relevant benefit of ribociclib plus NSAI are demonstrated, consistent with the increasing reduction in recurrence risk, and reinforce the benefit of ribociclib plus NSAI in the adjuvant setting across the broad NATALEE-eligible population.

D. Slamon, G. Hortobagyi, D. Stroyakovskiy et al. · 1 citation
Open access Nov 2026

Real-world outcomes of everolimus-based therapy after CDK4/6 inhibitor therapy in ER-positive/HER2-negative metastatic breast cancer: a multicenter registry-based study.

BACKGROUND Everolimus-based endocrine therapy is used for estrogen receptor-positive/human epidermal growth factor receptor 2-negative (ER-positive/HER2-negative) metastatic breast cancer after cyclin-dependent kinase 4/6 (CDK4/6) inhibitor treatment, but factors associated with treatment durability remain unclear. We...

Hikari Kiyohara, Toru Hanamura, Y. Sagara et al. · 0 citations
Open access Sep 2026

Real-world treatment patterns and associated outcomes in patients with HER2-positive unresectable or metastatic breast cancer: the HER2 REAL Study

This retrospective study shows heterogeneity in treatment patterns and survival outcomes in real-world patients with HER2-positive mBC, indicating the need for optimization of treatment in patients with HER2-positive mBC in real-world.

S. C. Lee, C. Barrios, W. Chung et al. · 0 citations
Open access 2026

The relationship between tumor-infiltrating lymphocytes, pathologic complete response, and event-free survival in patients with early-stage triple-negative breast cancer treated with the KEYNOTE-522 regimen in a real-world scenario

Introduction: Tumor-infiltrating lymphocytes (TILs) are established prognostic and predictive biomarkers in early-stage triple-negative breast cancer (eTNBC). The addition of pembrolizumab to neoadjuvant chemotherapy (NAC) improves outcomes, as demonstrated in the KEYNOTE-522 trial. The role of TILs in this setting war...

R. Bonadio, M. Monteiro, W. Lima et al. · 0 citations
Open access Sep 2026

A retrospective, observational cohort study of treatment patterns and outcomes among patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer in the United States following endocrine therapy

The findings reinforce the high unmet need in patients with HR+/HER2’s metastatic breast cancer whose disease has become resistant to ET, highlighting the need for effective treatments in this setting.

J. O'Shaughnessy, M. Rehnquist, N. Sadetsky et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.